Skip to content
Upcoming events
AEEDC Dubai 202719–21 January 2027World Health Expo (WHX) Dubai 202725–28 January 2027ChinaDental South China 20273–6 March 2027GermanyIDS 2027 — International Dental Show16–20 March 2027United StatesAAD Annual Meeting 202719–23 March 2027Dubai Derma 20276–8 April 2027Dental-Expo Moscow Spring 202726–29 April 2027France7th World Congress of Dermoscopy12–15 May 2027GermanyEADV Symposium 202720–22 May 2027United StatesASCO Annual Meeting 20274–8 June 2027ChinaSino-Dental 20279–12 June 2027White Nights 2027 — St. Petersburg International Oncology ForumUsually early JulyArmenian Medical World Congress 20278–10 July 2027Dental-Expo Moscow 2027Usually late SeptemberNetherlandsEADV Congress 202722–25 September 2027SpainEAO Congress 202723–25 September 2027CanadaCFAS Annual Meeting 202723–25 September 2027Russian Health Care Week 2027Usually December
Internal Medicine

STREAM trial: stopping statins after 70 was non-inferior at two years, but events were higher over longer follow-up

Senior female healthcare worker in a video call with a patient, wearing a stethoscope and lab coat.

Key facts

  • The STREAM trial randomised 1,880 adults aged 70 or older with at least two chronic conditions and no cardiovascular disease to stop or continue their statin.
  • Stopping was non-inferior to continuing for heart attack, ischaemic stroke or death at 2 years.
  • Over the full follow-up (up to 4 years), events occurred in 12.7% of those who stopped versus 9.2% of those who continued.
  • The results were published in the New England Journal of Medicine and presented at the AHA Scientific Sessions on 7 November 2026.

What happened

Swiss and US researchers led by Nicolas Rodondi randomly assigned older adults who had taken a statin for at least a year for primary prevention to discontinue or continue it. Participants had a mean age of 77.5 years and no history of heart attack, stroke or other established cardiovascular disease.

Why it matters

Many older adults take statins for years, and the benefit of continuing them for primary prevention in later life is uncertain, especially in people who already take many medicines. The trial gives randomised evidence on what happens when they are stopped.

Context

Stopping met the trial’s main safety test at 2 years, but over the longer follow-up rates were higher in the discontinuation group: heart attack 1.6% vs 0.6%, ischaemic stroke 2.2% vs 0.8% and death from any cause 9.8% vs 8%. The trial was open-label, about 14% of participants did not follow their assigned plan, and most follow-up was around 2 years. Commentators stress the result applies only to people without established cardiovascular disease and does not support a blanket recommendation to stop.

What it means for clinicians and students

  • Clinicians: deprescribing statins can be considered in selected older adults with multimorbidity, as a shared decision that weighs risks, preferences and life expectancy.
  • Patients: do not stop a statin on your own; discuss your personal risk with your doctor.
  • Students: note the difference between non-inferiority at a fixed time point and higher event rates over longer follow-up, and why primary and secondary prevention are different questions.

Source: Rodondi N, et al. Discontinuing statins in older adults without cardiovascular disease. New England Journal of Medicine, 7 November 2026 (STREAM trial); reported by HCPLive.

Source: HCPLive (NEJM, STREAM trial)